CD22.BB.z

CD22.BB.z is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Stanford University for the treatment of relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma (NHL). The CAR construct consists of a single-chain variable fragment (scFv) targeting the CD22 antigen, a 4-1BB (CD137) costimulatory domain, and a CD3ζ signaling domain. The manufacturing process involves collecting a patient's T cells, genetically modifying them using a lentiviral vector to express the CD22-directed CAR, and expanding them ex vivo using the Miltenyi CliniMACS Prodigy system. This therapy is particularly aimed at providing an alternative for patients who have progressed after CD19-targeted therapies.

Other names

CD22 CARCD-22 CARCD 22 CARAutologous CD22 CAR T cellsCD22-directed CAR T-cell therapyCD-22-directed CAR T-cell therapyCD 22-directed CAR T-cell therapy